EMA Authorised: Eliquis (apixaban) — Bristol-Myers Squibb / Pfizer EEIG

View source ↗

Summary

The EMA authorised Eliquis (apixaban) to prevent venous thromboembolism in patients undergoing arthroplasty, with Bristol-Myers Squibb/Pfizer EEIG as the market…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Eliquis (apixaban)

Snippet

Status: Authorised. Therapeutic area: Arthroplasty;Venous Thromboembolism. MAH: Bristol-Myers Squibb / Pfizer EEIG. Decision date: 01/04/2026